Insider Selling: Edwards Lifesciences Co. (NYSE:EW) VP Sells 9,500 Shares of Stock

Edwards Lifesciences Co. (NYSE:EW - Get Free Report) VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,189,770.56. The trade was a 16.83 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Edwards Lifesciences Price Performance

Shares of NYSE EW traded up $1.38 on Monday, hitting $70.67. The company's stock had a trading volume of 5,653,037 shares, compared to its average volume of 4,585,872. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a market capitalization of $41.55 billion, a price-to-earnings ratio of 10.14, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The stock has a 50 day moving average of $71.74 and a 200-day moving average of $70.34.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Remove Ads

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors have recently added to or reduced their stakes in the business. Versor Investments LP increased its position in Edwards Lifesciences by 102.5% during the third quarter. Versor Investments LP now owns 4,455 shares of the medical research company's stock worth $294,000 after purchasing an additional 2,255 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at $2,069,000. GSA Capital Partners LLP acquired a new stake in shares of Edwards Lifesciences during the 3rd quarter worth $481,000. Future Fund LLC increased its holdings in shares of Edwards Lifesciences by 37.8% during the 3rd quarter. Future Fund LLC now owns 15,898 shares of the medical research company's stock worth $1,074,000 after buying an additional 4,363 shares during the last quarter. Finally, Empower Advisory Group LLC raised its position in shares of Edwards Lifesciences by 25.8% in the 3rd quarter. Empower Advisory Group LLC now owns 705,878 shares of the medical research company's stock worth $46,581,000 after buying an additional 144,857 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on EW shares. Barclays increased their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Citigroup increased their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a "buy" rating in a research report on Wednesday, December 11th. Bank of America raised Edwards Lifesciences from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Morgan Stanley raised their target price on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an "equal weight" rating in a report on Wednesday, February 12th. Finally, Wolfe Research downgraded shares of Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.